Sidewinder Therapeutics vs Beam Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (36 vs 38)
Sidewinder Therapeutics logo

Sidewinder Therapeutics

EmergingBioTech

Oncology

Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that creates tumor-selective cancer drugs that only become active in the tumor microenvironment, reducing systemic toxicity.

AI VisibilityBeta
Overall Score
D36
Category Rank
#1 of 1
AI Consensus
51%
Trend
up
Per Platform
ChatGPT
47
Perplexity
44
Gemini
28

About

Sidewinder Therapeutics is developing conditionally activated cancer therapeutics — drugs engineered to remain inert in circulation and become pharmacologically active only when they reach the tumor microenvironment. The approach exploits the unique biochemical conditions of solid tumors (acidic pH, hypoxia, tumor-specific proteases) to trigger drug activation, allowing far higher doses to be delivered to tumors with dramatically reduced side effects in healthy tissues.

Full profile
Beam Therapeutics logo

Beam Therapeutics

GrowthBiotechnology

Base Editing Gene Therapy

Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.

AI VisibilityBeta
Overall Score
D38
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
44
Perplexity
34
Gemini
29

About

Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
38
#1
Category Rank
#1
51
AI Consensus
64
up
Trend
up
47
ChatGPT
44
44
Perplexity
34
28
Gemini
29
31
Claude
30
40
Grok
34

Key Details

Category
Oncology
Base Editing Gene Therapy
Tier
Emerging
Growth
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Sidewinder Therapeutics
Oncology
Only Beam Therapeutics
Base Editing Gene Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.